ACTRN12621001102864招募中2 期
Dapagliflozin in Patients with Type-2 Diabetes Admitted to Intensive Care: A Pilot Single-Centre, Feasibility Randomised Controlled Trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adult aged 18 years or greater
- •Expected to be admitted to the ICU until the day after tomorrow
- •Pre-existing diagnosis of Type-2 diabetes mellitus
- •Estimated Glomerular Filtration rate (eGFR) of less than 45 ml/min/1.73m2
- •Able to take medication enterically
排除标准
- •Diagnosis of Type-1 diabetes mellitus (T1DM)
- •Documented SGLT2 inhibitor intolerance
- •Hepatic impairment with aspartate transaminase [AST] or alanine transaminase [ALT] greater than 3x the upper limit of normal [ULN]; or total bilirubin greater than 2x ULN at time of enrolment
- •No enteric route for medication administration
- •Death is deemed to be imminent or inevitable during this admission
- •Patients with diabetic ketoacidosis
- •Pre-existing urinary tract infection
- •Hypernatraemia defined as a serum sodium levels equal to or greater than 150 mmol/L at the time of screening
- •Clinician deems enrolment in the study is not in the patient’s best interests
研究者
相似试验
尚未招募
不适用
Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liverJPRN-UMIN000026549Kagawa prefectural central hospital25
已完成
不适用
Effect of Dapagliflozin in patients with type 2 daibetes mellitusType 2 diabetes mellitusJPRN-UMIN000014922Iwasaki Naika Clinic50
尚未招募
4 期
Dapagliflozin in Acute Heart failureIRCT20220529055013N1Public Sector medical University160
已完成
不适用
A Real World Experience of Dapagliflozin in Type 2 DiabetesType2 DiabetesNCT02966626University of Malaya223
招募中
不适用
Dapagliflozin add-on to metformin therapy in diabetic patientsCTRI/2022/12/048622Aditya kumar